Technology ❯ Artificial Intelligence

Investment Opportunities

Market Trends AI Stocks Stock Analysis Market Analysis Stock Performance Stock Market Market Potential Stock Recommendations Stock Comparison Comparative Analysis High-Potential Stocks Stock Potential Stock Comparisons Tech Stocks Intel AI ETFs Diversification Strategies Productivity Sector Analysis Stock Market Analysis Big Tech Billionaire Investors Chip Ventures Corporate Leaders High Growth Stocks Startup Funding OpenAI Market Impact Stock Market Potential Market Comparison Growth Potential Growth Stocks Market Speculation

Oklo Surges as DOE Finalizes Radioisotope Pilot Deal and Company Halts Meitner-1 Pursuit

The company pivots to a DOE-backed isotope reactor to align with a renewed federal push on nuclear supply chains.

Bailard Tech Strategy Gains 9.36% in Q3, Trails Benchmarks as AI Plays Lead and Fiserv Lags

WBD Board Backs Netflix Deal, Rejects Paramount Cash Bid

Meta’s AI Spending Draws Scrutiny as Analysts Reaffirm Bullish Calls

Cramer Reaffirms Bullish View on Carvana After Massive Run

ASML Faces New Scrutiny Over Reported China Sales as Analysts Lift Price Targets

TSMC Expansion Gains Pace as U.S. Investment Talk Swells, Japan Site Paused for Redesign

Cameco Rallies on Canada–India Uranium Talks Despite EPS Miss and Guidance Cut

Bristol Myers and J&J Cast as Dividend Plays as Bayer’s FXIa Win Refocuses Pipeline Interest

Arrowhead Gains FDA Approval for Redemplo as Results Surge and Shares Hit Three-Year High

Oscar Health Surges on Reports of Two-Year ACA Subsidy Extension

Opendoor Jumps on D.E. Shaw Stake Disclosure, Dovish Fed Signals

Cramer Backs Abbott’s Exact Sciences Buy, Calling It a Pivotal Diagnostics Move

TSMC Tallies $4.7 Billion in Global Subsidies as Board Approves $14.98 Billion 2026 Expansion

Opendoor Sets Nov. 18 Record Date for Warrant Dividend as Meme Stock Whipsaws

Cramer Questions Duolingo’s Relevance After Soft Bookings Outlook

Pagaya Shares Jump as Q3 Profit and Cash Flow Beat Drive Guidance Raise

Cramer Calls Pfizer ‘Uninvestible’ After Q3 Beat, Citing No Growth Engine and Seagen Letdown

Rocket Lab Slides Before Q3 Results as Bulls and Skeptics Clash Over Outlook

Eli Lilly Unveils $3 Billion Netherlands Plant for Oral GLP-1 Medicines as Stock Rises